PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 41 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 2.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $586,276 | -18.5% | 56,537 | +12.6% | 0.00% | 0.0% |
| Q2 2023 | $718,935 | +307137.2% | 50,205 | +53.2% | 0.00% | – |
| Q1 2023 | $234 | -32.2% | 32,761 | +6.6% | 0.00% | – |
| Q4 2022 | $345 | -99.9% | 30,732 | +6.2% | 0.00% | – |
| Q3 2022 | $321,000 | +42.7% | 28,927 | +8.5% | 0.00% | – |
| Q2 2022 | $225,000 | -17.3% | 26,649 | +33.5% | 0.00% | – |
| Q1 2022 | $272,000 | -19.5% | 19,968 | +16.0% | 0.00% | – |
| Q4 2021 | $338,000 | -39.6% | 17,207 | -1.4% | 0.00% | -100.0% |
| Q3 2021 | $560,000 | +0.7% | 17,454 | +6.2% | 0.00% | 0.0% |
| Q2 2021 | $556,000 | +29.9% | 16,438 | +44.3% | 0.00% | 0.0% |
| Q1 2021 | $428,000 | +5.7% | 11,390 | -6.6% | 0.00% | 0.0% |
| Q4 2020 | $405,000 | +1.2% | 12,200 | +11.7% | 0.00% | 0.0% |
| Q3 2020 | $400,000 | -5.0% | 10,920 | -14.6% | 0.00% | 0.0% |
| Q2 2020 | $421,000 | +42.7% | 12,790 | +12.0% | 0.00% | 0.0% |
| Q1 2020 | $295,000 | +35.3% | 11,423 | +63.5% | 0.00% | – |
| Q4 2019 | $218,000 | – | 6,986 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 5,827,415 | $187,060,000 | 14.97% |
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $66,378,000 | 14.44% |
| Abingworth LLP | 1,203,135 | $38,512,000 | 8.74% |
| Penn Mutual Asset Management, LLC | 86,940 | $2,791,000 | 4.41% |
| GREAT POINT PARTNERS LLC | 220,863 | $7,090,000 | 1.65% |
| RA Capital Management | 3,115,008 | $99,992,000 | 1.39% |
| StepStone Group LP | 422,085 | $13,549,000 | 0.88% |
| Summit Rock Advisors, LP | 34,100 | $1,094,000 | 0.65% |
| Rhenman & Partners Asset Management AB | 186,210 | $5,977,000 | 0.42% |
| Eventide Asset Management | 600,000 | $19,260,000 | 0.25% |